Search

Displaying results 1521 - 1530 of 3181 in total
  1. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it p...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

    Categories: Purinergic P1 Receptor Agonists
  3. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, and when sufficient damage has been caused to pancreatic cells that the body is no

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  4. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  5. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y...

    Categories: Purinergic P2 Receptor Antagonists
  6. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  7. Drug

    Insulin detemir

    go.drugbank.com/drugs/DB01307
    ApprovedInvestigational

    prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  8. Drug

    Prolgolimab

    go.drugbank.com/drugs/DB16740
    Investigational

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  9. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  10. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavabl...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates